Dr. Garcia-Manero on Exciting Advances on the Horizon in MDS

Guillermo Garcia-Manero, MD, of the Department of Leukemia at MD Anderson Cancer Center, discusses where the field of hematologic oncology is headed.

—

Where do you see hematologic oncology headed, and what are some exciting happenings that you’re keeping an eye on in MDS?

Dr. Garcia-Manero: We are living through a transformation that is phenomenal. This applies to all malignant hematology. I think genomic knowledge has been transformative. Now we are into single cell analyses that has almost become routine. This is giving us a phenomenal understanding of hematopoiesis in these diseases. This allows us to elucidate new targets and clonal dynamics. We are also seeing the development of strong immunotherapeutics and CAR T-cells in lymphoid malignancies and now perhaps moving into myeloid malignancies. This, together with the ability to combine many of these agents, is going to transform the care of patients with MDS and AML.